Denali Therapeutics Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter financial report. The filing was signed February 26, 2021.
Business context
Denali is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases. It had no approved products and generated no product-sales revenue. Its strategy centers on genetically supported targets, blood-brain-barrier delivery technology, and biomarker-driven development. The company reported five programs in clinical studies and more than 15 in preclinical development.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration revenue | $335.7 million | $26.7 million |
| Research and development expense | $212.6 million | $193.4 million |
| General and administrative expense | $60.3 million | $46.5 million |
| Operating income (loss) | $62.7 million | $(213.2) million |
| Net income (loss) | $71.1 million | $(197.6) million |
| Net cash provided by (used in) operations | $416.2 million | $(151.6) million |
- Revenue growth and the return to GAAP profitability were driven principally by the Biogen collaboration. Of the $335.7 million in revenue, $307.4 million was associated with Biogen; Denali had no product sales.
- FY2020 operating cash flow included a $297.4 million increase in related-party contract liabilities. It therefore reflects collaboration cash and revenue timing, not recurring product economics.
- At December 31, 2020, cash and cash equivalents were $507.1 million and marketable securities were $995.3 million, totaling approximately $1.502 billion. Current assets were $1.496 billion and current liabilities were $71.7 million.
- Total liabilities were $453.7 million, including collaboration contract liabilities and operating lease liabilities. The filing reports no debt balance in the presented balance sheet. Undiscounted operating lease obligations were $97.7 million.
- Accumulated deficit was $354.4 million. Management said available cash, cash equivalents and marketable securities were expected to fund projected operations for at least 12 months after the filing date; this estimate depends on assumptions and spending plans.
Material changes and significant developments
- Biogen paid $560 million in collaboration upfront payments in October 2020 and purchased 13.31 million Denali shares for $465 million in September. The stock proceeds were financing, not revenue. The collaboration arrangements also provide potential future milestones, cost sharing, profit sharing and royalties.
- Denali recognized $306.5 million for the Biogen LRRK2 program license and $0.9 million for option research services. A $297.4 million related-party contract liability remained at year-end, largely for a deferred option right and remaining research services.
- Research and development expense rose 10% and general and administrative expense rose 30% year over year. R&D personnel costs increased; lower LRRK2 external costs, including Biogen cost sharing, partly offset increases elsewhere.
- Denali sold 9.0 million shares in a January 2020 follow-on offering for net proceeds of approximately $193.9 million. Shares outstanding increased from 96.2 million at year-end 2019 to 120.5 million at year-end 2020.
Outlook, pipeline, and key risks
- DNL310 for Hunter syndrome: A Phase 1/2 trial began in August 2020. In February 2021, Denali reported interim biomarker and safety results from five patients after three months; these are early, small-cohort findings, not evidence of clinical efficacy. Denali planned a pivotal Phase 2/3 trial in the first half of 2022.
- DNL151 (BIIB122) for Parkinson’s disease: Selected with Biogen for late-stage development. The companies expected to begin two studies by year-end 2021; a Phase 1b patient trial completed in January 2021 met target- and pathway-engagement goals.
- DNL343: A Phase 1 healthy-volunteer trial was underway; initial results were expected in the first half of 2021, with a Phase 1b ALS trial planned for the second half of 2021.
- RIPK1: Denali and Sanofi paused DNL747 after dose- and duration-related nonclinical toxicity findings constrained dose escalation. DNL788 began a Phase 1 trial in December 2020. Sanofi paused further DNL758 development for COVID-19 but planned a cutaneous lupus Phase 2 trial in the first half of 2021.
- Denali and its partners rely on early clinical, biomarker and preclinical evidence; none of the programs had reached pivotal testing or regulatory approval. Key risks include clinical failure or delay, safety findings, patient recruitment, COVID-19 disruption, third-party manufacturing and supply dependence, competition, intellectual-property uncertainty, and reliance on collaborators.
- Denali reported no material litigation proceedings. A shareholder derivative action concerning director compensation was settled subject to court approval; the company said its settlement obligations were not material. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Separate recurring operating performance from collaboration-related revenue recognition, deferred contract liabilities, and one-time financing proceeds.
- Check subsequent clinical-trial disclosures for DNL310’s clinical outcomes and durability, and for safety, dose selection, and enrollment in planned studies.
- Confirm whether DNL151 late-stage studies and the DNL343 and DNL788 development timelines proceeded as planned.
- Assess future R&D spending, collaboration cost-sharing obligations, potential milestone receipts, and the assumptions underlying management’s cash-runway estimate.
- Monitor dilution, stock-based compensation, partner option decisions, manufacturing capacity, and the status of DNL747-related safety learnings.